In patients with metastatic melanoma, or non-small cell lung cancer, the in vitro responsiveness of PBMC-derived CD4 T cells to IFN-β was more effective at predicting subsequent response to α-PD1 therapy than was the state of the CD4 T cells directly ex vivo. This evidence concerns the gene CD4 and metastatic melanoma.